Key features
Actively managed, globally oriented fund with focused exposure to an industry with significant long-term growth potential
Emphasis on companies with franchise sustainability and attractive valuations
Portfolio manager with extensive experience in both the healthcare and asset management industries
Daily pricing
as of
06/05/2023
NAV 1-day net change
0.16
Total net assets
as of
04/30/2023
All share classes
$831.3 million
Overview
Fund identifiers |
NASDAQ |
DLHIX |
CUSIP |
24610E408 |
Benchmark and peer group
Portfolio
Market cap (median) Source: FactSet
$1.7 billion
Market cap (weighted average) Source: FactSet
$137.8 billion
Portfolio turnover (last fiscal year)
1%
International equities & depositary receipts
13.7%
Top 10 holdings
as of 05/31/2023
Holdings are as of the date indicated and subject to change.
List may exclude cash and cash equivalents. Please see the Fund's complete list of holdings for more information.
Holdings based by issuer.
REGENERON PHARMACEUTICALS INC.
7.50
ELI LILLY AND COMPANY
7.11
UNITEDHEALTH GROUP INC
5.28
INTRA-CELLULAR THERAPIES INC
3.41
Total % Portfolio in Top 10 holdings - 48.20%
Sector allocation
as of 05/31/2023
List may exclude cash, cash equivalents, and exchange-traded funds (ETFs) that are used for cash management purposes. Please see the Fund’s complete list of holdings for more information.
Blue chip medical products
45.3%
Healthcare services
11.6%
Small/mid-cap medical products
9.1%
Distribution history - annual distributions (Institutional Class)1,2
Distributions ($ per share)
1If a Fund makes a distribution from any source other than net income, it is required to provide shareholders with a notice disclosing the source of such distribution (each a "Notice"). The amounts and sources of distributions reported above and in each Notice are only estimates and are not provided for tax reporting purposes. Each Fund will send each shareholder a Form 1099 DIV for the calendar year that will provide definitive information on how to report the Fund's distributions for federal income tax purposes. The information in the table above will not be updated to reflect any subsequent recharacterization of dividends and distributions. Click here to see recent Notices pertaining to the Fund (if any).
2Information on return of capital distributions (if any) is only provided from June 1, 2014 onward.
3Includes both short- and long-term capital gains.
Management
Liu-Er Chen, CFA
-
Managing Director, Chief Investment Officer — Emerging Markets and Healthcare
-
Start date on the Fund:
September 2007
-
Years of industry experience:
27
-
Read bio
Liu-Er Chen
Managing Director, Chief Investment Officer — Emerging Markets and Healthcare
Liu-Er Chen heads the firm’s global Emerging Markets team, and he is also the portfolio manager for Delaware Healthcare Fund, which launched in September 2007. Prior to joining Macquarie Investment Management (MIM) in September 2006 in his current position, he spent nearly 11 years at Evergreen Investment Management Company, where he most recently worked as managing director and senior portfolio manager. He co-managed the Evergreen Emerging Markets Growth Fund from 1999 to 2001, and became the Fund’s sole manager in 2001. He was also the sole manager of the Evergreen Health Care Fund since its inception in 1999. Chen began his career at Evergreen in 1995 as an analyst covering Asian and global healthcare stocks, before being promoted to portfolio manager in 1998. Prior to his career in asset management, Chen worked for three years in sales, marketing, and business development for major American and European pharmaceutical and medical device companies. He received his medical education in China, and he has experience in medical research at both the Chinese Academy of Sciences and Cornell Medical School. He holds an MBA with a concentration in management from Columbia Business School.
Fees
The table below describes the fees and expenses that you may pay if you buy, hold, and sell shares of the Fund. You may pay other fees, such as brokerage commissions and other fees to financial intermediaries, which are not reflected in the table below. You may quality for sales-charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Delaware Funds by Macquarie. More information about these and other discounts is available from your financial intermediary, in the Fund’s Prospectus under the section entitled “About your account,” and in the Fund’s statement of additional information (SAI) under the section entitled “Purchasing Shares.”
Shareholder fees |
Maximum sales charge (load) imposed on purchases as a percentage of offering price |
none |
Maximum contingent deferred sales charge (load) as a percentage of original purchase price or redemption price, whichever is lower |
none |
Annual fund operating expenses |
Management fees |
0.82% |
Distribution and service (12b-1) fees |
none |
Other expenses |
0.17% |
Total annual fund operating expenses |
0.99% |
Fee waivers and expense reimbursements |
(0.03%) |
Total annual fund operating expenses after fee waivers and expense reimbursements |
0.96% |
Please see the prospectus and SAI for additional information.
1Net expense ratio reflects a contractual waiver of certain fees/and/or expense reimbursements from July 29, 2022 through July 29, 2023. Please see the fee table in the Fund's prospectus for more information.
Institutional Class shares are available only to certain investors. See the prospectus for more information.
Resources
Fact sheet and commentaries
You are now leaving the Delaware Funds by Macquarie website
The link you have selected will take you to a website not controlled by Delaware Funds by Macquarie. Your web browser will automatically redirect you to the site in a few moments. Delaware Funds by Macquarie is not responsible for the content of the website you are about to visit.
Thank you for visiting the Delaware Funds by Macquarie website.
Other than Macquarie Bank Limited (MBL), none of the entities noted are authorised deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these entities do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of these entities, unless noted otherwise.
The Funds are distributed by Delaware Distributors, L.P., an affiliate of Macquarie Investment Management Business Trust (MIMBT), Macquarie Management Holdings, Inc., and Macquarie Group Limited. Macquarie Investment Management (MIM), a member of Macquarie Group, refers to the companies comprising the asset management division of Macquarie Group Limited and its subsidiaries and affiliates worldwide.
Separately managed account advisory services are provided by Delaware Capital Management (DCM), a series of MIMBT. Separately managed account advisory services are referred through Delaware Capital Management Advisers, Inc., an SEC-registered investment advisor.